Background: The pathophysiology of takotsubo syndrome (TTS) is unclear so far. There is strong association of the occurrence of TTS and malignant diseases. An association between malignant diseases and myocardial infarction (MI) was found recently and ascribed to common molecular and lifestyle mechanisms. Aim: To compare the outcome of patients with MI or TTS and malignant diseases in a matched cohort. Methods: Patients with TTS or with MI (n ¼ 138 per group) were matched for age and sex and assessed retrospectively and prospectively. Occurrence of malignant diseases and clinical outcome was followed up over 4 years. Results: At the time of the index event, 8 (5.8%) MI patients and 17 (12.3%) TTS patients were already diagnosed with cancer. During follow up, the rate of patients who developed cancer was significantly higher in the TTS group than in the MI group (log rank P ¼ 0.01). Mortality was higher in the TTS group, but also in the subgroup of TTS patients with cancer (log rank P < 0.05). In the multivariate analysis, male gender, renal impairment and the history of cancer was associated with an increased risk for death. Conclusions: Patients with TTS have more often malignant diseases than patients with MI. Cancer patients with TTS have a worse clinical outcome. The underlying mechanism is unclear yet, but the results point at TTS being the syndrome of an extracardiac disease rather than a disease of cardiac origin. Longer and closer follow up of patients with TTS and further studies addressing the mechanism of TTS are needed.
Introduction
Takotsubo syndrome (TTS) is characterized by an acute onset of cardiac ventricular wall motion dysfunction, which presents clinically with symptoms of acute heart failure, such as dyspnea, or of myocardial ischemia, such as angina pectoris. 1 The underlying pathophysiology is unclear so far. The factor causing TTS most widely discussed is a sudden excess of catecholamines, 2 which leads to structural alterations of the myocardium and, subsequently, to its dysfunction. 3 As published recently, there is strong association of the occurrence of TTS and malignant diseases. 4, 5 The diagnosis of malignant disease was timely closely related to the occurrence of TTS, but a higher than expected rate of malignant diseases was observed during a follow up of 4 years as well. This was associated with a higher rate of the development of adverse events and a shorter time of event-free survival and overall survival. 4 These findings have led to the hypothesis that TTS and cancer are both the manifestations of a catecholamine-driven disease entity. 4 Recently, an association between malignant diseases and myocardial infarction (MI) was found in a large populationbased study, 6 with a biphasic pattern during the 15 years of follow up. While the increased rate of malignomas within the first 6 months after MI was ascribed primarily to the early detection due to the thorough examination of MI patients, the later increase of cancer was ascribed to common risk factors inducing both atherosclerosis and cancer development. 6 There are clear guidelines for the treatment of patients with MI for secondary prevention. 7, 8 The therein recommended drugs, for example aspirin, and non-pharmacologic factors, such as life style modification, might be able to attenuate cancer development. In addition, close surveillance of MI patients might allow detecting cancer signs at an early state of disease. In contrary, until now no guidelines exist for the follow up of patients after TTS, not to mention for the long-term use of drugs with probable anti-cancer effect. Based on our previous results, we have recently suggested the need for long-term follow up of TTS patients with extra attention to cancer development. In the current study, we compared the occurrence of malignant diseases in patients with MI versus with TTS and their outcome during a follow up period of almost 5 years to test the need for long-term care of patients surviving the TTS event.
Materials and methods

Patients
Data of consecutive patients presenting with TTS from 2003 to 2017 were included in the study retrospectively and prospectively (TTS group). TTS was defined by the Mayo clinic criteria. 9 To assess the diagnosis of TTS, the angiograms, echocardiograms and ECGs were reviewed by two independent experienced cardiologists. Cardiology, University Hospital Mannheim, and were subsequently treated with percutaneous coronary intervention (PCI) and stent implantation, were assessed from the department's database. Out of more than 500 patients, a group of MI patients was matched to the TTS patients by age and sex, giving 138 patients with either disease. Baseline characteristics of demographic and clinical data were assessed by chart review, as were in-hospital events (arrhythmias, cardiac rupture, thromboembolic events, pulmonary congestion with use of non-invasive positive-pressure ventilation, intubation, use of a temporary pacemaker, use of inotropic agents, death). MI patients were followed up retrospectively. This study was conducted in compliance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of University Medical Centre Mannheim.
Study end point
The end point of the study was the occurrence of malignancy in TTS patients compared to MI patients. Additionally, the outcome during follow up, including all-cause mortality, stroke, 
Results
Baseline characteristics of patients with malignant diseases at index event
After matching by age and sex, there were 138 patients in both the myocardial infarction (MI) group and in the Takotsubo syndrome group (TTS). Baseline characteristic of both groups are shown in Table 1 . Patients with TTS had higher heart rate and ECG anomalies (ST elevation, QTc prolongation) than patients with MI. Similarly, left ventricular function was lower in TTS patients than in MI patients (Table 1) . Regarding previous medical history, patients with MI had more often the "traditional" pro-atherogenic risk factors such as diabetes mellitus, arterial hypertension or adiposity than patients with TTS (Table 1) .
Malignant disease at time of index event
At the time of the index event, eight (5.8%) patients of the MI group and 17 (12.3%) patients of the TTS group suffered from malignant diseases (P ¼ 0.059). The distribution of tumors at admission is depicted in detail in Figure 1A and B for both groups. Baseline characteristics of patients with malignant diseases of both groups are presented in the Supplementary Table S1 . Even when comparing these subgroups, patients with TTS and cancer had higher heart rate and lower left ventricular ejection fraction than patients with MI and cancer. Incidence of atrial fibrillation was higher in TTS patients as well (Supplementary Table S1 ).
In-hospital events
In the TTS group, ventilation therapy (both non-invasive and invasive) was more often required than in the MI group. In the TTS patients, thromboembolic events were observed more frequently than in the MI group (Table 2) .
New malignancies during follow up
During the follow up of more than 4 years (1601 6 546 days in TTS and 1190 6 845 days in MI), three cases of cancer were diagnosed in the MI group, but 13 cases in the TTS group (P ¼ 0.01). Several patients were diagnosed with more than one malignant disease, thus, at the end of the follow up time, 11 patients of the MI group and 28 patients of the TTS group were suffering from cancer. In the Kaplan-Meier analysis, the rate of patients who developed cancer was significantly higher in the TTS group than in the MI group (log rank P ¼ 0.01; Figure 2 ). The kinds of cancer newly diagnosed during follow up are depicted in Figure 3A and B for both groups.
Higher mortality in cancer patients with TTS
Compared to patients with MI, the mortality during follow up was significantly increased in patients of the TTS group (35 [25%] vs. 17 [12%], P < 0.01, Table 3 ). The higher risk of death in the TTS group was shown clearly in the Kaplan-Meier analysis, as depicted in Figure 4 . The risk of non-cardiovascular death was higher in TTS patients (15 [10.9%]) than in MI patients (2 [1.4%], P < 0.01), while the risk of cardiovascular death was comparable (Table 3 ). In patients suffering from cancer, mortality was higher in TTS patients than in MI patients as well, and was predominantly caused by non-cardiovascular events (Supplementary Table S2 , P ¼ 0.08). The frequency of stroke, life-threatening arrhythmia, and recurrence of event or thromboembolic event did not differ between both groups during follow up (data not shown). The Kaplan-Meier analysis clearly demonstrated a higher risk of death in the TTS group with malignant diseases (log rank P ¼ 0.03, Figure 5 ). The univariate analysis demonstrated an association of several parameters with an increased risk of 5-year mortality for TTS patients. In the multivariate analysis, only male gender, renal impairment and the history of cancer was associated with an increased risk of death (Table 4) .
Discussion
In the current study, we found a higher prevalence of cancer in TTS patients compared to an age-and sex-matched group of MI patients at the time of the cardiovascular event. During follow up, new cases of cancer were more often found in TTS patients than in MI patients. In addition, mortality of patients with TTS was higher than of patients with MI during the follow up time. This was also true for the subgroup of patients suffering from TTS and cancer.
An association of both diseases, TTS and MI, with cancer has been shown recently, 4, 6 with a prevalence of cancer of 22% in TTS and of 8% in MI. Although both studies are not comparable regarding sample size and study design, both show a reliable increase of cancer when compared to patients without MI (hazard ratio for cancer 1.46 6 ) or when compared to the national cancer registry (age-adjusted crude rate of the 1-year-prevalence of all types of cancer of 1.4% in males
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). The association of atherosclerosis, the main cause for MI, with cancer is likely based on common pathomechanisms of both processes. Among the factors known so far are lifestyle factors such as tobacco smoking, alcohol intake and physical inactivity, 11 while common disease entities are diabetes mellitus, obesity and hypertension.
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Underlying molecular and genetic pathways comprise impaired cellular lipid or glucose metabolism, inflammation, oxidative stress, pro-thrombotic state, and genetic modifiers. 12 Indeed, in our study MI patients had more often these "traditional risk factors" than TTS patients. Any possible mechanisms underlying the association between TTS and cancer are less well known. This is certainly in part due to the uncertainty of the pathophysiology of TTS itself. Although patients are often classified as having myocardial infarction due to cardiac symptoms and elevation of cardiac biomarkers upon presentation, these signs are only the common final pathway of myocardial damage and its clinical symptoms, while the onset mechanisms of TTS are unclear yet. The observation of the association of pheochromocytoma or paraganglioma with TTS had stimulated the discussion of TTS being mediated by catecholamines. 3 For malignant diseases not secreting catecholamines themselves, a probable association is less clear. However, as catecholamines are a potential factor for cancer development, we have recently hypothesized that TTS and cancer are manifestations of an individually too high a catecholaminergic state. 4 In favor for this notion is the observation of higher heart rate, higher incidence of atrial fibrillation and lower left ventricular ejection fraction in the group with TTS and cancer than in the group with MI and cancer in the current study. As the baseline characteristics and treatment modalities or in hospital events were comparable between TTS and MI patients, it is impossible to define clear indicators for the future development of malignant disease. Thus, further search of a valid biomarker or an array of markers of TTS, either of biochemical or of clinical nature, is needed to identify patients at risk for both disease entities. Altogether the findings lead to the hypothesis that TTS is not a primarily cardiac disease which shares the pathophysiologic mechanisms of induction with cancer, as hypothesized for MI, but that TTS is a symptom of an extracardiac disease, of which cancer is either another symptom, or the basic disease triggering TTS. As described before, 13,14 mortality was higher in TTS patients than in MI patients. For TTS patients, cause of death was mainly of non-cardiac origin, while the cause of death in the MI group was mainly of cardiac origin, in accord with the higher prevalence of classical risk factors for cardiovascular diseases in this group. In contrast, patients with TTS presented more often several known factors of worse outcome in TTS such as atrial fibrillation, 15 thromboembolic events 16 or QT prolongation. 17 Thus, as in hospital course and treatment was comparable between both groups, as was occurrence of death from cardiovascular cause, the traditional risk factors are not suited to predict death for patients with TTS, especially not for the group of patients with TTS and cancer. These results might indicate again that TTS might be the manifestation of an extracardiac origin, in this case, for an advanced stage of malignant disease, equivalent to the occurrence of metastasis. The results show the need for a close, prolonged follow up of patients with TTS to check for malignant disease, but vice versa, also for checking cancer patient closely for occurrence of TTS. As there are no guidelines for the long-term treatment or follow up of TTS, patients with TTS may easily be lost to regular care, especially if symptoms of TTS have resolved well after the event and a malignant disease is not diagnosed at this time. Similarly, cancer patients who develop TTS should be followed up to test whether they have a worse outcome than cancer patients without TTS. As we have observed a predominance of colorectal cancer (CRC) in TTS, these patients might be the most promising group to study, especially as there are well-defined follow up guidelines of CRC. 18 Such study might need a very close follow up scheme with many time points, as any symptoms such as dyspnea or fatigue might be ascribed primarily to the fact of suffering from cancer. In addition, there is the overlap to chemotherapy induced atherosclerosis or myocardial damage, 19, 20 which might be difficult to discern a cardiac event from
"pure" TTS. We cannot rule out that the lower incidence of cancer during follow up in the MI group was in part caused by anti-cancer effects of cardiovascular drugs, particularly, of aspirin. Anticancer effects of aspirin have been observed in studies involving a great number of patients during the recent years. 21 For molecular mechanisms, the inhibition of platelet function was mainly discussed, in that aspirin prevents release of granules containing pro-inflammatory mediators, which in turn induce a pro-inflammatory and, subsequently, pro-cancerogenic cellular phenotype. 22 The intake of aspirin prior to the index event in the MI group may have played a part in preventing cancer in our study, especially colorectal cancer, which was indeed the predominant kind of cancer in TTS but not in MI at time of admission. A recent meta-analysis described a reduction of colon and colorectal cancer by intake of aspirin, with a timedependency of the anti-cancer effect, starting after 3 years of intake 23 and showing highest benefit when taken for at least 5 years.24 However, the current study was not designed to test effects of particular drugs. The impact of aspirin on TTS outcome is examined currently in a prospective study of our institution. Even more important for improvement of survival after TTS than regular pharmacologic treatment might be regular clinical follow up.
Limitations
We did not record the exact time of tumor diagnosis prior to index event or during follow up. This would have perhaps allowed for more precise computing of an association between index event and tumor disease. Cancer was noted down as disease without recording its actual stage; thus we cannot rule out the presence of a microscopic disease stage already present at index event, nor state an association about the "activity" of the disease and the occurrence of MI or TTS. Matching patients by age and sex is an arbitrary criterion of matching. Additional matching by presence of risk factors might have allowed identifying or excluding further factors possibly affecting the outcome; however, the number of MI patients needed for matching if following this approach is unrealistic to collect. From our data, we cannot study the effect of pharmacologic treatment on outcome.
Summary
The Takotsubo syndrome (TTS) is more closely associated with the occurrence of malignant diseases than myocardial infarction (MI), despite of common pathways of atherosclerosis and cancer development of the latter. The long-term outcome of patients with TTS is worse than the outcome of MI patients, both in the whole group as well as in the subgroup of cancer patients. The mechanisms for these observations are not known yet. TTS might be a manifestation of extracardiac diseases such as cancer. The current results point at the need for longer and closer follow up of patients with TTS, as well as for further studies addressing the mechanism of TTS.
Ethical approval
This study was conducted in compliance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the University Medical Centre Mannheim. This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Access to data
Data can be obtained from the authors upon request.
